Cryoport, Inc. (NASDAQ: CYRX) has developed one of the most
comprehensive solution platforms available today in the life sciences-focused
cryogenic logistics space, with a suite of proprietary technologies such as its
signature Cryoport Express® (http://dtn.fm/jGrs5) dry vapor dewars for
materials that need to be kept at frozen temperatures, as well as its
Cryoportal™ logistics management platform and SmartPak II™ continuous,
geo-sensing monitoring system (http://dtn.fm/53nP7). Reinforced by a rock-solid
commitment to 24/7 customer support and cold chain logistics consulting
spanning risk assessment, lane qualification and process flow – the company’s
portfolio of industry-leading technologies has propelled CYRX to the forefront
of the sector, allowing the company to secure such sweetheart deals as the
recent strategic partnership with $2.4 billion market cap, diversified metals
manufacturing giant, Worthington Industries (NYSE: WOR).
This latest deal will see Worthington’s CryoScience by
Taylor Wharton Division, one of the most influential and competent
manufacturers in the space today, designing and manufacturing biostorage and
logistics hardware for CYRX’s life sciences solutions. It’s the kind of cozy
deal that will open big doors for the company, granting its already much sought
after cold chain logistics solutions the ability to satisfy a much broader
client mix, and enabling the company to dynamically scale support for
proliferating client commercialization efforts.
Cryoport is no stranger to marching into the gap like this,
as news of the Worthington partnership came just days after the company’s
announcement on April 11 regarding the launch of its new Temperature Controlled
Logistics Consulting Division, which was organized to answer feverish demand from
a global and burgeoning cellular-based therapies market. The deluge of
cell-based immunotherapy technologies currently in the soon-to-be $2.45
trillion-plus personalized medicine pipeline (http://dtn.fm/rm0Kj) has created
a perfect storm for storage and transportation logistics players and only a
tiny handful of key players, such as CYRX, are positioned to capitalize on
runaway demand for the kind of planning and strategies needed to help
effectively develop and deploy temperature sensitive/personalized therapies.
The broader global cryogenic equipment market is on-track to
hit upwards of $25 billion by 2022 (http://dtn.fm/VwY57), with the Asia-Pacific
region seen as the strongest segment at around $7.83 billion projected by 2019
(http://dtn.fm/sa9FD). This is a target-rich environment for a company like
Cryoport, which is actively working in regenerative medicine in support of some
64 different clinical trials, including Perseus PCI’s Phase II2b melanoma and
ovarian cancer clinical trial, as well as ImmunoCellular Therapeutics’ (NYSE:
IMUC) registrational Phase III clinical trial of ICT-107 immunotherapy in
aggressive brain cancer, which spans 400-plus newly-diagnosed glioblastoma
patients at 120 sites throughout North America and Europe.
Any questions as to just how capable Cryoport is when it
comes to securing additional traction within the space, should be quickly put
to rest by one look at the company’s earlier deal in March of 2016 with one of
the planet’s undisputed leaders in logistics, UPS (NYSE: UPS). UPS launching
its biotech, pharma and medical device industry-tailored Temperature True® Cryo
solution in Europe, which allows customers to keep products at -150°C for 10
days using Cryoport Express containers’ dry vapor liquid nitrogen technology, gives
CYRX access to the global network of 51 UPS healthcare-dedicated facilities,
and sets the company up for continued success alongside UPS, which serves more
than 220 countries and territories worldwide.
For more information, visit www.cryoport.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment